

Press Briefing Day 2 - SATURDAY, JUNE 16, 2018

A new anti-CD22 CAR-T immunotherapy saved the lives of children with leukemia

Dr Jing Pan, Beijing Boren Hospital, Beijing, China ([Abstract S832](#))

Our study shows that CD22-CAR-T cell therapy is a highly effective and safe treatment option for pediatric r/r B-ALL patients even after they failed CD19-CAR-T therapy and also-HCT. It gives these otherwise untreatable patients a new hope. [MAIN SLIDES](#)

iNNOVATE Study: Ibrutinib plus Rituximab for patients with Waldenström's Macroglobulinemia

Dr Meletios Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece ([Abstract S852](#))

Conclusion:

Based on the data from this study, ibrutinib+rituximab could become a standard treatment option for WM. [MAIN SLIDES](#)

Answering the unmet need in one of the most common types of lymphoma: It's as simple as A-D-C

Dr Laurie H. Sehn, BC Cancer Agency, Vancouver, Canada ([Abstract S802](#))

Based on these results, polatuzumab vedotin has been granted Breakthrough Therapy Designation by the US Food and Drug Administration and PRIME (PRiority MEdicines) designation by the European Medicines Agency for R/R DLBCL. [MAIN SLIDES](#)

EHA Topics-in-Focus: Making CAR-T cells happen in Europe

John Gribben, Barts Cancer Institute, London, United Kingdom

EHA Topics-in-Focus: From the basics of sickle cell disease to where we are now

Maria Cappellini, University of Milan-Foundation IRCCS Policlinico Hospital, Italy